NxStage Medical, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 66 rows in 2017. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2017-12-20: Reporting owner Swan Winifred L; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2017-12-12: Reporting owner FUNARI ROBERT G; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2017-12-12: Reporting owner FUNARI ROBERT G; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2017-11-15: Reporting owner Swan Winifred L; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2017-12-20 | Swan Winifred L Officer (SVP and General Counsel) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,000 17,542 owned after | $11.03 exercise price | 2017-12-21 | |
| 2017-12-12 | FUNARI ROBERT G Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −18,196 0 owned after | $13.60 exercise price | 2017-12-14 | |
| 2017-12-12 | FUNARI ROBERT G Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,173 0 owned after | $11.27 exercise price | 2017-12-14 | |
| 2017-11-15 | Swan Winifred L Officer (SVP and General Counsel) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,000 20,542 owned after | $11.03 exercise price | 2017-11-15 | |
| 2017-10-20 | TOWSE MATTHEW W Officer (SVP and Chief Financial Office) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,030 0 owned after | $14.05 exercise price | 2017-10-23 | |
| 2017-10-20 | Swan Winifred L Officer (SVP and General Counsel) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,000 23,542 owned after | $11.03 exercise price | 2017-10-23 | |
| 2017-09-20 | Swan Winifred L Officer (SVP and General Counsel) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,000 26,542 owned after | $11.03 exercise price | 2017-09-21 | |
| 2017-09-20 | TOWSE MATTHEW W Officer (SVP and Chief Financial Office) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,300 4,030 owned after | $14.05 exercise price | 2017-09-21 | |
| 2017-09-12 | Mixer Jean K Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −18,196 0 owned after | $13.60 exercise price | 2017-09-13 | |
| 2017-08-21 | TOWSE MATTHEW W Officer (SVP and Chief Financial Office) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,300 8,330 owned after | $14.05 exercise price | 2017-08-23 | |
| 2017-08-15 | Swan Winifred L Officer (SVP and General Counsel) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,000 29,542 owned after | $11.03 exercise price | 2017-08-15 | |
| 2017-08-07 | Turk Joseph E Jr Officer (President) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,000 25,897 owned after | $11.03 exercise price | 2017-08-08 | |
| 2017-08-07 | Turk Joseph E Jr Officer (President) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −12,000 36,958 owned after | $14.66 exercise price | 2017-08-08 | |
| 2017-08-07 | Turk Joseph E Jr Officer (President) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,669 7,542 owned after | $18.48 exercise price | 2017-08-08 | |
| 2017-08-07 | Turk Joseph E Jr Officer (President) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,331 5,392 owned after | $18.59 exercise price | 2017-08-08 | |
| 2017-08-03 | Turk Joseph E Jr Officer (President) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,000 32,897 owned after | $11.03 exercise price | 2017-08-04 | |
| 2017-07-20 | Swan Winifred L Officer (SVP and General Counsel) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,000 32,542 owned after | $11.03 exercise price | 2017-07-21 | |
| 2017-07-20 | TOWSE MATTHEW W Officer (SVP and Chief Financial Office) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,300 12,630 owned after | $14.05 exercise price | 2017-07-21 | |
| 2017-06-20 | TOWSE MATTHEW W Officer (SVP and Chief Financial Office) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,300 16,930 owned after | $14.05 exercise price | 2017-06-21 | |
| 2017-06-15 | Swan Winifred L Officer (SVP and General Counsel) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,000 35,542 owned after | $11.03 exercise price | 2017-06-16 | |
| 2017-06-08 | Turk Joseph E Jr Officer (President) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,250 7,723 owned after | $18.59 exercise price | 2017-06-12 | |
| 2017-05-25 | Peters James J Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,643 15,643 owned after | $22.78 exercise price | 2017-05-26 | |
| 2017-05-25 | REID PERPER Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,643 15,643 owned after | $22.78 exercise price | 2017-05-26 | |
| 2017-05-25 | MOORE CRAIG W Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,643 15,643 owned after | $22.78 exercise price | 2017-05-26 | |
| 2017-05-25 | Mixer Jean K Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,643 15,643 owned after | $22.78 exercise price | 2017-05-26 | |
| 2017-05-25 | LEWIS EARL R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,643 15,643 owned after | $22.78 exercise price | 2017-05-26 | |
| 2017-05-25 | Giannini Daniel A Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,643 15,643 owned after | $22.78 exercise price | 2017-05-26 | |
| 2017-05-25 | FUNARI ROBERT G Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,643 15,643 owned after | $22.78 exercise price | 2017-05-26 | |
| 2017-05-25 | Donigan Heyward R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,643 15,643 owned after | $22.78 exercise price | 2017-05-26 | |
| 2017-05-22 | TOWSE MATTHEW W Officer (SVP and Chief Financial Office) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,300 21,230 owned after | $14.05 exercise price | 2017-05-23 | |
| 2017-05-15 | Swan Winifred L Officer (SVP and General Counsel) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,000 38,542 owned after | $11.03 exercise price | 2017-05-15 | |
| 2017-05-10 | Turk Joseph E Jr Officer (President) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −250 9,973 owned after | $18.59 exercise price | 2017-05-11 | |
| 2017-04-20 | Donigan Heyward R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,582 10,784 owned after | $21.73 exercise price | 2017-05-26 | |
| 2017-04-20 | Swan Winifred L Officer (SVP and General Counsel) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,000 41,542 owned after | $11.03 exercise price | 2017-04-20 | |
| 2017-04-20 | TOWSE MATTHEW W Officer (SVP and Chief Financial Office) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,300 25,530 owned after | $14.05 exercise price | 2017-04-20 | |
| 2017-04-03 | Brown Robert S. Officer (President, NxStage Kidney Care) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −11,917 59,592 owned after | $15.58 exercise price | 2017-04-04 | |
| 2017-03-20 | Swan Winifred L Officer (SVP and General Counsel) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,223 0 owned after | $18.59 exercise price | 2017-03-22 | |
| 2017-03-20 | TOWSE MATTHEW W Officer (SVP and Chief Financial Office) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,300 29,830 owned after | $14.05 exercise price | 2017-03-22 | |
| 2017-03-10 | REID PERPER Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,272 0 owned after | $14.99 exercise price | 2017-03-13 | |
| 2017-03-09 | Brown Robert S. Officer (President, NxStage Kidney Care) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +39,884 39,884 owned after | $27.89 exercise price | 2017-03-13 | |
| 2017-03-09 | Swan Winifred L Officer (SVP and General Counsel) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +39,884 39,884 owned after | $27.89 exercise price | 2017-03-13 | |
| 2017-03-09 | Turk Joseph E Jr Officer (President) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +99,711 99,711 owned after | $27.89 exercise price | 2017-03-13 | |
| 2017-03-09 | TOWSE MATTHEW W Officer (SVP and Chief Financial Office) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +49,855 49,855 owned after | $27.89 exercise price | 2017-03-13 | |
| 2017-03-09 | Burbank Jeffrey H Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +149,567 149,567 owned after | $27.89 exercise price | 2017-03-13 | |
| 2017-03-07 | Brown Robert S. Officer (President, NxStage Kidney Care) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −20,000 45,618 owned after | $16.66 exercise price | 2017-03-07 | |
| 2017-03-01 | Turk Joseph E Jr Officer (President) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,039 0 owned after | $9.96 exercise price | 2017-03-01 | |
| 2017-02-21 | TOWSE MATTHEW W Officer (SVP and Chief Financial Office) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,300 34,130 owned after | $14.05 exercise price | 2017-02-23 | |
| 2017-02-17 | Turk Joseph E Jr Officer (President) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,000 48,958 owned after | $14.66 exercise price | 2017-02-21 | |
| 2017-02-15 | Swan Winifred L Officer (SVP and General Counsel) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,549 0 owned after | $18.48 exercise price | 2017-02-15 | |
| 2017-02-10 | Burbank Jeffrey H Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −123,900 0 owned after | $9.96 exercise price | 2017-02-14 | |
| 2017-02-10 | Burbank Jeffrey H Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,697 39,062 owned after | $18.48 exercise price | 2017-02-14 | |
| 2017-02-10 | Burbank Jeffrey H Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,591 36,273 owned after | $18.59 exercise price | 2017-02-14 | |
| 2017-02-10 | Turk Joseph E Jr Officer (President) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 10,223 owned after | $18.59 exercise price | 2017-02-13 | |
| 2017-02-03 | Brown Robert S. Officer (President, NxStage Kidney Care) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,000 21,958 owned after | $14.66 exercise price | 2017-02-06 | |
| 2017-02-02 | Brown Robert S. Officer (President, NxStage Kidney Care) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,000 34,958 owned after | $14.66 exercise price | 2017-02-02 | |
| 2017-02-02 | Turk Joseph E Jr Officer (President) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,669 10,211 owned after | $18.48 exercise price | 2017-02-02 | |
| 2017-02-02 | Turk Joseph E Jr Officer (President) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,000 39,897 owned after | $11.03 exercise price | 2017-02-02 | |
| 2017-02-02 | Turk Joseph E Jr Officer (President) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,000 54,958 owned after | $14.66 exercise price | 2017-02-02 | |
| 2017-02-01 | Brown Robert S. Officer (President, NxStage Kidney Care) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,000 47,958 owned after | $14.66 exercise price | 2017-02-02 | |
| 2017-02-01 | MOORE CRAIG W Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,272 0 owned after | $14.99 exercise price | 2017-02-02 | |
| 2017-01-26 | Brown Robert S. Officer (President, NxStage Kidney Care) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,000 8,897 owned after | $11.03 exercise price | 2017-01-26 | |
| 2017-01-25 | Brown Robert S. Officer (President, NxStage Kidney Care) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −20,000 15,897 owned after | $11.03 exercise price | 2017-01-26 | |
| 2017-01-24 | Brown Robert S. Officer (President, NxStage Kidney Care) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,000 35,897 owned after | $11.03 exercise price | 2017-01-26 | |
| 2017-01-23 | Brown Robert S. Officer (President, NxStage Kidney Care) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,000 50,897 owned after | $11.03 exercise price | 2017-01-23 | |
| 2017-01-20 | TOWSE MATTHEW W Officer (SVP and Chief Financial Office) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,300 38,430 owned after | $14.05 exercise price | 2017-01-23 | |
| 2017-01-20 | Swan Winifred L Officer (SVP and General Counsel) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,000 44,542 owned after | $11.03 exercise price | 2017-01-23 |